BRPI1001935A2 - Compostos de ácido 2-mercaptociclopentanocarboxílico, um processo para sua preparação e composições farmacêuticas contendo-os - Google Patents

Compostos de ácido 2-mercaptociclopentanocarboxílico, um processo para sua preparação e composições farmacêuticas contendo-os Download PDF

Info

Publication number
BRPI1001935A2
BRPI1001935A2 BRPI1001935-9A BRPI1001935A BRPI1001935A2 BR PI1001935 A2 BRPI1001935 A2 BR PI1001935A2 BR PI1001935 A BRPI1001935 A BR PI1001935A BR PI1001935 A2 BRPI1001935 A2 BR PI1001935A2
Authority
BR
Brazil
Prior art keywords
group
mercaptocyclopentanocarboxylic
pharmaceutical compositions
compositions containing
acid compounds
Prior art date
Application number
BRPI1001935-9A
Other languages
English (en)
Inventor
Gloanec Philippe
De Nanteuil Guillaume
Parmentier Jean-Gilles
Guillouzic Anne-Françoise
Verbeuren Tony
Rupin Alain
Mennecier Philippe
Vallez Marie-Odile
Quirion Jean-Charles
Jubault Philippe
Boyer Nicolas
Original Assignee
Les Laboratoires Servier
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Les Laboratoires Servier filed Critical Les Laboratoires Servier
Publication of BRPI1001935A2 publication Critical patent/BRPI1001935A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
    • C07C323/50—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton
    • C07C323/61—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atom of at least one of the thio groups bound to a carbon atom of a ring other than a six-membered aromatic ring of the carbon skeleton
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C327/00—Thiocarboxylic acids
    • C07C327/20—Esters of monothiocarboxylic acids
    • C07C327/32—Esters of monothiocarboxylic acids having sulfur atoms of esterified thiocarboxyl groups bound to carbon atoms of hydrocarbon radicals substituted by carboxyl groups
    • C07C327/34—Esters of monothiocarboxylic acids having sulfur atoms of esterified thiocarboxyl groups bound to carbon atoms of hydrocarbon radicals substituted by carboxyl groups with amino groups bound to the same hydrocarbon radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D205/00—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom
    • C07D205/02—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings
    • C07D205/04—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/34—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/54—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/55—Acids; Esters

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Obesity (AREA)
  • Cardiology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Rheumatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Emergency Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Endocrinology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Hydrogenated Pyridines (AREA)
  • Pyridine Compounds (AREA)

Abstract

COMPOSTOS DE ÁCIDO 2-MERCAPTOCICLO- PENTANOCARBOXÍLICO, UM PROCESSO PARA SUA PREPARAÇçO E COMPOSIÇÕES FARMACÊUTICAS CONTENDO-OS. em que: R~1~ representa um átomo de hidrogênio ou um grupo de fórmula COR4, ou R~1~ representa um grupo de fórmula (A): R~2~ representa um grupo de fórmula NR~5~R~6~, ou R~2~ representa um grupo heterocíclico contendo nitrogênio, um grupo arila ou um grupo hetero- arila, R~3~ representa um átomo de hidrogênio ou um grupo alquila, m representa um número inteiro entre 1 e 6 inclusive, n representa 0,1 ou 2, seus isômeros áticos, e também sais de adição dos mesmos com um ácido farmaceuticamente aceitável. Medicamentos.
BRPI1001935-9A 2009-06-26 2010-06-24 Compostos de ácido 2-mercaptociclopentanocarboxílico, um processo para sua preparação e composições farmacêuticas contendo-os BRPI1001935A2 (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR0903111A FR2947266B1 (fr) 2009-06-26 2009-06-26 Nouveaux derives d'acide 2-mercaptocyclopentanecarboxylique, leur procede de preparation et les compositions pharmaceutiques qui les contiennent

Publications (1)

Publication Number Publication Date
BRPI1001935A2 true BRPI1001935A2 (pt) 2012-03-06

Family

ID=41594318

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI1001935-9A BRPI1001935A2 (pt) 2009-06-26 2010-06-24 Compostos de ácido 2-mercaptociclopentanocarboxílico, um processo para sua preparação e composições farmacêuticas contendo-os

Country Status (28)

Country Link
US (1) US8309341B2 (pt)
EP (1) EP2272826A1 (pt)
JP (1) JP5238757B2 (pt)
KR (1) KR101187394B1 (pt)
CN (1) CN101928241A (pt)
AP (1) AP2010005304A0 (pt)
AR (1) AR078415A1 (pt)
AU (1) AU2010202563A1 (pt)
BR (1) BRPI1001935A2 (pt)
CA (1) CA2707647A1 (pt)
CL (1) CL2010000694A1 (pt)
CO (1) CO6300113A1 (pt)
CR (1) CR11494A (pt)
CU (1) CU20100133A7 (pt)
EA (1) EA017867B1 (pt)
EC (1) ECSP10010292A (pt)
FR (1) FR2947266B1 (pt)
GT (1) GT201000184A (pt)
IL (1) IL206405A0 (pt)
MA (1) MA32340B1 (pt)
MX (1) MX2010007070A (pt)
NI (1) NI201000111A (pt)
NZ (1) NZ586444A (pt)
PE (1) PE20110022A1 (pt)
TW (1) TWI380813B (pt)
UY (1) UY32702A (pt)
WO (1) WO2010149888A1 (pt)
ZA (1) ZA201004398B (pt)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR3046793B1 (fr) * 2016-01-14 2018-01-05 Les Laboratoires Servier Nouveaux derives de phosphinanes et azaphosphinanes, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
CN109467506B (zh) * 2017-09-07 2021-12-07 江苏瑞科医药科技有限公司 一种取代苯乙酸衍生物的制备方法

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4315031A (en) * 1977-09-01 1982-02-09 Science Union Et Cie Thiosubstituted amino acids
US4385062A (en) * 1980-01-09 1983-05-24 Gruppo Lepetit S.P.A. 1-[(-2-Mercaptocycloalkyl)carbonyl]-L-proline derivatives, the process for their manufacture, the intermediates for their synthesis and their use as anti-hypertensive agents
JPS5750955A (en) * 1980-09-12 1982-03-25 Hokko Chem Ind Co Ltd Oxime carbamate derivative and insecticide
JPH0565258A (ja) * 1991-07-03 1993-03-19 Nippon Bayeragrochem Kk 酢酸アニリド誘導体および除草剤
NZ253524A (en) * 1992-05-29 1997-01-29 Procter & Gamble Pharma Sulphur-containing phosphonate derivatives and medicaments (for treating abnormal calcium and phosphate metabolism)
PL361054A1 (en) * 2000-08-17 2004-09-20 Pfizer Inc. Substituted imidazoles as tafia inhibitors
KR100954651B1 (ko) * 2002-03-21 2010-04-27 바이엘 쉐링 파마 악티엔게젤샤프트 혈장 카르복시펩티드분해효소 ｂ 억제제
EP1551864B1 (de) * 2002-10-04 2011-11-09 DSM IP Assets B.V. Substrate zur Bestimmung von TAFI(a)
DE102004020186A1 (de) * 2004-04-22 2005-11-17 Aventis Pharma Deutschland Gmbh Heterocyclylessigsäuren als Inhibitoren von TAFla

Also Published As

Publication number Publication date
CN101928241A (zh) 2010-12-29
FR2947266A1 (fr) 2010-12-31
UY32702A (es) 2010-12-31
AU2010202563A1 (en) 2011-01-20
EP2272826A1 (fr) 2011-01-12
CO6300113A1 (es) 2011-07-21
TWI380813B (zh) 2013-01-01
MX2010007070A (es) 2011-01-05
EA017867B1 (ru) 2013-03-29
NZ586444A (en) 2011-09-30
ECSP10010292A (es) 2011-06-30
JP5238757B2 (ja) 2013-07-17
MA32340B1 (fr) 2011-06-01
KR101187394B1 (ko) 2012-10-02
CA2707647A1 (fr) 2010-12-26
US8309341B2 (en) 2012-11-13
NI201000111A (es) 2010-12-17
CL2010000694A1 (es) 2011-05-06
IL206405A0 (en) 2010-12-30
AP2010005304A0 (en) 2010-06-30
WO2010149888A1 (fr) 2010-12-29
CR11494A (es) 2010-09-13
AR078415A1 (es) 2011-11-09
FR2947266B1 (fr) 2011-06-17
GT201000184A (es) 2012-04-30
TW201105322A (en) 2011-02-16
US20100330064A1 (en) 2010-12-30
KR20110000516A (ko) 2011-01-03
JP2011006416A (ja) 2011-01-13
EA201000867A1 (ru) 2010-12-30
CU20100133A7 (es) 2012-02-15
PE20110022A1 (es) 2011-02-04
ZA201004398B (en) 2011-03-30

Similar Documents

Publication Publication Date Title
BR112014027181A2 (pt) derivados de benzamida para a inibição da atividade de abl1, abl2 e bcr-abl1
BR112015021983A8 (pt) compostos heterocíclicos, composições e usos dos mesmos
BR112014027584A2 (pt) compostos e composições para inibir a atividade de abl1, abl2 e bcr-abl1
BR112014026383A2 (pt) derivados de benzamida para inibir a atividade de abl1, abl2 e bcr-abl1
BRPI0908353B8 (pt) composto ou um sal farmaceuticamente aceitavel do mesmo e composição farmaceutica
EA200701176A1 (ru) Новые соединения нафталина, способ их получения и фармацевтические композиции, содержащие их
BRPI0900983B8 (pt) composto de diometina, processo para a síntese do mesmo, composição farmacêutica e seu uso
BR112018008397A2 (pt) derivados de di-hidroimidazopirazinona úteis no tratamento do câncer
CU24030B1 (es) Nuevos derivados de benzotiadiazepinas, su procedimiento de preparación y composiciones farmacéuticas que los contienen
BRPI0804091A2 (pt) compostos de 1,2,4,5-tetrahidro-3h-benzazepina, processo para sua preparação e composições farmacêuticas que os contêm
BRPI0511999A (pt) compostos como antagonistas de ccr5
BR112015001207A8 (pt) derivados de carbamato/ureia, seus usos, composição farmacêutica, forma livre e seu método de preparação
BRPI0720742B8 (pt) derivados de heteroaril pirrolidinil e piperidinil cetona, seus usos e composição farmacêutica compreendo os mesmos
CU20100157A7 (es) Nuevos derivados dihidroindolonas, su procedimiento de preparación y las composiciones farmacéuticas que los contienen
BR0308765A (pt) Compostos (4,2-dissubstituìdo-tiazol-5-il)amina como inibidores de pde7
UA87284C2 (ru) Соединения фенилпиридилпиперазина, способ их получения и фармацевтическая композиция, которая их содержит
BRPI0923324A2 (pt) Composto, uso de um composto, método para inibição da dna girase e/ou topoisomerase iv bacteriana em um animal de sangue quente, e, processo para preparar um composto.
UA91645C2 (ru) Соединения индола, способ их получения и фармацевтическая композиция (варианты), которая их содержит
BRPI1001935A2 (pt) Compostos de ácido 2-mercaptociclopentanocarboxílico, um processo para sua preparação e composições farmacêuticas contendo-os
BR112012006233B8 (pt) composto de fórmula i, composição farmacêutica e usos de um composto
UY32333A (es) Derivados cuaternarios de piridina y utilización de los mismos
UA91646C2 (ru) Соединения индола, способ их получения и фармацевтическая композиция (варианты), которая их содержит
UY33927A (es) Nuevos derivados dihidro-oxazolobenzodiazepinonas, su procedimiento de preparación y las composiciones farmacéuticas que los contienen
CU20130037A7 (es) Nuevos derivados dihidrobenzoxatiazepinas, su procedimiento de preparación y las composiciones farmacéuticas que los contienen
BRPI0900030A2 (pt) compostos de 1h-indol-1-il-uréia, um processo para sua preparação e composições farmacêuticas contendo-os

Legal Events

Date Code Title Description
B03A Publication of a patent application or of a certificate of addition of invention [chapter 3.1 patent gazette]
B11A Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing
B11Y Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette]